Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
Abstract
:1. Introduction
2. Methods
2.1. Study Design
2.2. Patients
2.3. Treatment
2.4. Definition of Response
2.5. Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. Treatment Efficacy
3.3. Treatment Efficacy in Bio-Failure Cases
3.4. Analysis of VDZ Dropout Patients
3.5. Early Clinical Remission Can Be a Predictor of Long-Term Remission
3.6. Safety
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ungaro, R.; Mehandru, S.; Allen, B.P.; Peyrin-Biroulet, L.; Colombel, J.F. Ulcerative colitis. Lancet 2017, 389, 1756–1770. [Google Scholar] [CrossRef]
- Toshifumi, H.; Makoto, N.; Tetsuji, K.; Fukunori, K.; Takashi, S. Low dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative Colitis. J. Gastroenterol. 2003, 38, 740–746. [Google Scholar]
- McLean, L.P.; Shea-Donohue, T.; Cross, K.R. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy 2012, 4, 883–898. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fedyk, E.R.; Wyant, T.; Yang, L.L.; Csizmadia, V.; Burke, K.; Yang, H.; Kadambi, V.J. Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm. Bowel Dis. 2012, 18, 2107–2119. [Google Scholar] [CrossRef] [PubMed]
- Soler, D.; Chapman, T.; Yang, L.L.; Wyant, T.; Egan, R.; Fedyk, E.R. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther. 2009, 330, 864–875. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hesterberg, P.E.; Winsor-Hines, D.; Briskin, M.J.; Soler-Ferran, D.; Merrill, C.; Mackay, C.R.; Newman, W.; Ringler, D.J. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7. Gastroenterology 1996, 111, 1373–1380. [Google Scholar] [CrossRef] [PubMed]
- Pouillon, L.; Stappan, J.V.; Bossuyt, P.; Danese, S.; Peyrin-Biroulet, L. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Pract. Res. Clin. Gastroenterol. 2018, 32–33, 17–25. [Google Scholar] [CrossRef] [PubMed]
- Feagan, B.G.; Rutgeers, P.; Sands, B.E.; Hanauer, S.; Colombel, J.-F.; Sandborn, W.J.; Assche, G.V.; Axler, J.; Kim, H.J.; Danese, S.; et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2013, 369, 699–710. [Google Scholar] [CrossRef] [Green Version]
- Feagan, B.G.; Patel, H.; Colombel, J.-F.; Rubin, D.T.; Jamed, A.; Mody, R.; Lasch, K. Effect of vedolizumab on health-related quality of life in patients with ulcerative colitis: Results from the randomized GEMINI 1 trial. Aliment. Pharmacol. Ther. 2017, 45, 264–275. [Google Scholar] [CrossRef] [PubMed]
- Loftus, E.V., Jr.; Colombel, J.-F.; Feagan, B.G.; Vermeire, S.; Sandborn, W.J.; Sands, B.E.; Danese, S.; D’Haens, G.R.; Kaser, A.; Panaccione, R.; et al. Long-term efficacy of vedolizumab for ulcerative colitis. J. Crohns Colitis 2017, 11, 400–411. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Satoshi, M.; Kenji, W.; Haruhiko, O.; Takanori, K.; Toshiyuki, M.; Yasuo, S.; Mitsuhiro, S.; Kenkichi, S.; Kazunori, O.; Tetsuharu, H.; et al. Vedolizumab in Japanese patients with ulcerative colitis: A phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE 2019, 14, e0212989. [Google Scholar]
- Kenji, W.; Satoshi, M.; Haruhiko, O.; Takanori, K.; Toshiyuki, M.; Yasuo, S.; Mitsuhiro, S.; Kenkichi, S.; Kazunori, O.; Tetsuharu, H.; et al. Effects of vedolizumab in Japanese patients with Crohn’s disease:a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. J. Gastroenterol. 2020, 55, 291–306. [Google Scholar]
- Dignass, A.; Eliakim, R.; Magro, F.; Maaser, C.; Chowers, Y.; Geboes, K.; Mantzaris, G.; Reinisch, W.; Colombel, J.-F.; Vermeire, S.; et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: Definitions and diagnosis. J. Crohns Colitis 2012, 6, 965–990. [Google Scholar] [CrossRef] [PubMed]
- Annese, V.; Daperno, M.; Rutter, M.D.; Amiot, A.; Bossuyt, P.; East, J.; Ferrante, M.; Gotz, M.; Katsanos, K.H.; KieBlich, R.; et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J. Crohns Colitis 2013, 7, 982–1018. [Google Scholar] [CrossRef] [Green Version]
- Baars, J.E.; Nuij, V.J.; Oldenburg, B.; Kuipers, E.J.; Woude, C.J. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm. Bowel Dis. 2012, 18, 1634–1640. [Google Scholar] [CrossRef] [PubMed]
- Rosenberg, L.; Lawlor, G.O.; Zenlea, T.; Goldsmith, J.D.; Gifford, A.; Falchuk, K.R.; Wolf, J.L.; Cheifetz, A.S.; Robson, S.C.; Moss, A.C. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm. Bowel Dis. 2013, 19, 779–784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shiho, T.; Jun, K.; Sakiko, H.; Asuka, N.; Daisuke, T.; Toshihiro, I.; Yuusaku, S.; Masahiro, T.; Keita, H.; Hiroyuki, O.; et al. Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test. Am. J. Gastroenterol. 2015, 110, 873–880. [Google Scholar]
- Martine, D.V.; De Vos, M.; Louis, E.J.; Jahnsen, J.; Vandervoort, J.G.; Noman, M.; Dewit, O.; D’haens, G.R.; Franchimont, D.; Baert, F.J.; et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm. Bowel Dis. 2013, 19, 2111–2117. [Google Scholar]
- Shinazaki, S.; Matsuoka, K.; Iijima, H.; Mizuno, S.; Serada, S.; Fujimoto, M.; Arai, N.; Koyama, N.; Morii, E.; Watanabe, M.; et al. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J. Crohns Colitis 2017, 11, 84–91. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reinisch, W.; Bressler, B.; Curtis, R.; Parikh, A.; Yang, H.; Rosario, M.; Røseth, A.; Danese, S.; Feagan, B.; Sands, B.E.; et al. Fecal calprotectin responses following induction therapy with vedolizumab in moderate to severe ulcerative colitis: A post hoc analysis of GEMINI 1. Inflamm. Bowel Dis. 2019, 25, 803–810. [Google Scholar] [CrossRef] [Green Version]
- Eliadou, E.; Day, A.S.; Thompson-Fawcett, M.W.; Gearry, R.B.; Rowbotham, D.S.; Walmsley, R.; Schultz, M.; Inns, S.J. New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis. N. Z. Med. J. 2015, 128, 63–76. [Google Scholar] [PubMed]
- Lichtiger, S.; Present, D.H.; Kornbluth, A.; Gelernt, I.; Bauer, J.; Galler, G.; Michelassi, F.; Hanauer, S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 1994, 330, 1841–1845. [Google Scholar] [CrossRef] [PubMed]
- Van Assche, G.; D’haens, G.; Noman, M.; Vermeire, S.; Hiele, M.; Asnong, K.; Arts, J.; D’Hoore, A.; Penninckx, F.; Rutgeerts, P. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003, 125, 1025–1031. [Google Scholar] [CrossRef]
- Yoko, Y.; Mikio, K.; Ken, F.; Koji, K.; Kazuko, N.; Koji, N.; Tomoaki, K.; Yoshio, O.; Masaki, I.; Nobuyuki, H.; et al. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: Markers of response to GMA. BMC Gastroenterol. 2013, 13, 27. [Google Scholar]
- Mohammed Vashist, N.; Samaan, M.; Mosli, M.H.; Parker, C.E.; MacDonald, J.K.; Nelson, S.A.; Zou, G.Y.; Feagan, B.G.; Khanna, R.; Jairath, V. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst. Rev. 2018, 1, CD011450. [Google Scholar] [CrossRef]
- Schroeder, K.W.; Tremaine, W.J. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987, 317, 1625–1629. [Google Scholar] [CrossRef]
- Boal Carvalho, P.; Cotter, J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs 2017, 77, 159–173. [Google Scholar] [CrossRef]
- Gisbert, J.P.; Chaparro, M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: From basic science to clinical practice. J. Crohns Colitis 2020, 14, 694–709. [Google Scholar] [CrossRef]
- Dulai, P.S.; Singh, S.; Jiang, X.; Peerani, F.; Narula, N.; Chaudrey, K.; Whitehead, D.; Hudesman, D.; Lukin, D.; Swaminath, A.; et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: Results from the US VICTORY consortium. Am. J. Gastroenterol. 2016, 111, 1147–1155. [Google Scholar] [CrossRef]
- Wils, P.; Bouhnik, Y.; Michetti, P.; Michetti, P.; Flourie, B.; Brixi, H.; Bourrier, A.; Allez, M.; Duclos, B.; Grimaud, J.C.; et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin. Gastroenterol. Hepatol. 2016, 14, 242–250. [Google Scholar] [CrossRef] [Green Version]
- Mavroudis, G.; Magnusson, M.K.; Isaksson, S.; Sundin, J.; Semiren, M.; Ohman, L.; Strid, H. Mucosal and systemic immune profiles differ during early and late phases of the disease in patients with active ulcerative colitis. J. Crohns Colitis 2019, 13, 1450–1458. [Google Scholar] [CrossRef] [PubMed]
- Shelton, E.; Allegretti, J.R.; Stevens, B.; Lucci, M.; Khalili, H.; Nguyen, D.D.; Yajnik, V. Efficacy of vedolizumab as induction therapy in refractory IBD patients: A multicenter cohort. Inflamm. Bowel Dis. 2015, 21, 2879–2885. [Google Scholar] [CrossRef] [PubMed]
- Sands, B.E.; Peyrin-Biroulet, L.; Loftus, E.V., Jr.; Danese, S.; Colombel, J.F.; Törüner, M.; Jonaitis, L.; Abhyankar, B.; Chen, J.; Rogers, R.; et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N. Engl. J. Med. 2019, 381, 1215–1226. [Google Scholar] [CrossRef]
- Singh, S.; Murad, M.H.; Fumery, M.; Dulai, P.S.; Sandborn, W.J. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: An updated network meta-analysis. Clin. Gastroenterol. Hepatol. 2020, 18, 2179–2191. [Google Scholar] [CrossRef]
- Neeraj, N.; Wong, E.C.L.; Marshall, J.K.; Colombel, J.F.; Dulai, P.S.; Reinisch, W. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. Clin. Gastroenterol. Hepatol. 2022, 20, 1588–1597. [Google Scholar]
- Makoto, N.; Kenji, W.; Satoshi, M.; Haruhiko, O.; Toshiyuki, M.; Yasuo, S.; Ursos, L.; Shigeru, S.; Mitsuhiro, S.; Tetsuharu, H.; et al. Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. J. Gastroenterol. Hepatol. 2022, 37, 81–88. [Google Scholar]
- Stallmach, A.; Langbein, C.; Atreya, R.; Bruns, T.; Dignass, A.; Ende, K.; Hampe, J.; Hartmann, F.; Neurath, M.F.; Maul, J.; et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease a prospective multicenter observational study. Aliment. Pharmacol. Ther. 2016, 44, 1199–1212. [Google Scholar] [CrossRef]
- Feagan, B.G.; Rubin, D.T.; Danese, S.; Vermeire, S.; Abhyankar, B.; Sankoh, S.; James, A.; Smyth, M. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin. Gastroenterol. Hepatol. 2017, 15, 229–239. [Google Scholar] [CrossRef]
- Baumgart, D.C.; Bokemeyer, B.; Drabik, A.; Stallmach, A.; Schreiber, S. Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice—A nationwide consecutive German cohort study. Aliment. Pharmacol. Ther. 2016, 43, 1090–1102. [Google Scholar] [CrossRef]
- Kopylov, U.; Ron, Y.; Avni-Biron, I.; Koslowsky, B.; Waterman, M.; Daher, S.; Dotan, I. Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease the Israeli real-world experience. Inflamm. Bowel Dis. 2017, 23, 404–408. [Google Scholar] [CrossRef]
- Lenti, M.V.; Levison, S.; Avni-Biron, I.; Koslowsky, B.; Waterman, M.; Daher, S.; Ungar, B.; Yanai, H.; Maharshak, N.; Ben-Bassat, O.; et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. Dig. Liver Dis. 2018, 50, 1299–1304. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sandborn, W.J.; Colombel, J.F.; Panaccione, R.; Dulai, P.S.; Rosario, M.; Cao, C.; Barocas, M.; Lasch, K. Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: A GEMINI 1 post hoc analysis. J. Crohns Colitis 2018, 13, 172–181. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arijs, I.; Hertogh, G.D.; Lemmens, B.; Van Lommel, L.; de Bruyn, M.; Vanhove, W.; Cleynen, I.; Machiels, K.; Ferrante, M.; Schuit, F.; et al. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut 2017, 67, 43–52. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nagahori, M.; Watanabe, K.; Satoshi, M.; Haruhiko, O.; Takanori, K.; Toshiyuki, M.; Yasuo, S.; Philippe, P.; Lyann, U.; Shigeru, S.; et al. Symptomatic response with vedolizumab as a predictive factor in Japanese Anti-TNFα-naive patients with ulcerative colitis: A post hoc analysis of a randomized, placebo-controlled phase 3 trial. Digestion 2021, 102, 742–752. [Google Scholar] [CrossRef] [PubMed]
- Daisuke, S.; Minoru, M.; Ryo, O.; Sotao, T.; Shintaro, M.; Tatsuya, M.; Miki, M.; Akihito, S.; Mari, H.; Jun, M.; et al. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open 2021, 5, 1056–1062. [Google Scholar]
(n = 87) | |||
---|---|---|---|
Age, Mean ± SD (range) | 45.2 ± 14.0 (20–86) | ||
Sex, male: female (n) | 47:40 | ||
Disease duration in years, mean ± SD (range) | 9.4 ± 7.5 (1–33) | ||
Remission induction: maintenance (n) | 72:15 | ||
Clinical Activity, mean ± SD (range) | Lichtiger CAI 1 | 7.7 ± 4.6 (0–17) | |
Location of colitis, n (%) | Pancolitis | 56 (64.4%) | |
Left-sided colitis | 31 (35.6%) | ||
Mayo endoscopic subscore, n (%) | 0 | 13 (14.9%) | |
1 | 11 (12.6%) | ||
2 | 33 (41.3%) | ||
3 | 30 (37.5%) | ||
Baseline data, mean ± SD | C-reactive protein (mg/dL) | 1.5 ± 1.2 | |
Hemoglobin (g/dL) | 12.3 ± 2.3 | ||
Bio-naïve, n (%) | 53 (60.9%) | ||
Bio-failure, n (%): Prior bio use | 34 (39.1%) | 1 | 22 (25.3%) |
2 | 11 (12.6%) | ||
3 | 1 (1.2%) | ||
Concomitant drug, n (%) | 5-Aminosalicylate | 78 (89.7%) | |
Prednisolone | 36 (41.4%) | ||
Azathioprine | 33 (37.9%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Haga, K.; Shibuya, T.; Osada, T.; Sato, S.; Fukuo, Y.; Kobayashi, O.; Yamada, T.; Asaoka, D.; Ito, K.; Nomura, K.; et al. Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis. Biomedicines 2022, 10, 2526. https://doi.org/10.3390/biomedicines10102526
Haga K, Shibuya T, Osada T, Sato S, Fukuo Y, Kobayashi O, Yamada T, Asaoka D, Ito K, Nomura K, et al. Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis. Biomedicines. 2022; 10(10):2526. https://doi.org/10.3390/biomedicines10102526
Chicago/Turabian StyleHaga, Keiichi, Tomoyoshi Shibuya, Taro Osada, Shunsuke Sato, Yuka Fukuo, Osamu Kobayashi, Toshio Yamada, Daisuke Asaoka, Kentaro Ito, Kei Nomura, and et al. 2022. "Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis" Biomedicines 10, no. 10: 2526. https://doi.org/10.3390/biomedicines10102526